全文获取类型
收费全文 | 4193篇 |
免费 | 348篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 104篇 |
妇产科学 | 105篇 |
基础医学 | 491篇 |
口腔科学 | 313篇 |
临床医学 | 518篇 |
内科学 | 986篇 |
皮肤病学 | 28篇 |
神经病学 | 258篇 |
特种医学 | 176篇 |
外科学 | 535篇 |
综合类 | 75篇 |
一般理论 | 2篇 |
预防医学 | 386篇 |
眼科学 | 66篇 |
药学 | 326篇 |
1篇 | |
中国医学 | 3篇 |
肿瘤学 | 130篇 |
出版年
2021年 | 55篇 |
2020年 | 28篇 |
2019年 | 52篇 |
2018年 | 62篇 |
2017年 | 50篇 |
2016年 | 51篇 |
2015年 | 57篇 |
2014年 | 126篇 |
2013年 | 138篇 |
2012年 | 204篇 |
2011年 | 195篇 |
2010年 | 91篇 |
2009年 | 104篇 |
2008年 | 196篇 |
2007年 | 189篇 |
2006年 | 148篇 |
2005年 | 187篇 |
2004年 | 218篇 |
2003年 | 188篇 |
2002年 | 161篇 |
2001年 | 148篇 |
2000年 | 152篇 |
1999年 | 129篇 |
1998年 | 62篇 |
1997年 | 48篇 |
1996年 | 44篇 |
1995年 | 46篇 |
1994年 | 42篇 |
1993年 | 36篇 |
1992年 | 86篇 |
1991年 | 76篇 |
1990年 | 99篇 |
1989年 | 82篇 |
1988年 | 80篇 |
1987年 | 83篇 |
1986年 | 76篇 |
1985年 | 68篇 |
1984年 | 74篇 |
1983年 | 63篇 |
1982年 | 26篇 |
1981年 | 29篇 |
1980年 | 32篇 |
1979年 | 39篇 |
1978年 | 31篇 |
1977年 | 30篇 |
1976年 | 30篇 |
1974年 | 35篇 |
1971年 | 28篇 |
1968年 | 27篇 |
1966年 | 26篇 |
排序方式: 共有4547条查询结果,搜索用时 375 毫秒
101.
102.
103.
O. Pelkonen P. Myllynen P. Taavitsainen A. R. Boobis P. Watts B. G. Lake 《Xenobiotica; the fate of foreign compounds in biological systems》2013,43(6):321-343
1. The ability of various in vitro systems for CYP enzymes (computer modelling, human liver microsomes, precision-cut liver slices, hepatocytes in culture, recombinant enzymes) to predict various aspects of in vivo metabolism and kinetics of carbamazepine (CBZ) was investigated. 2. The study was part of the EUROCYP project that aimed to evaluate relevant human in vitro systems to study drug metabolism. 3. CBZ was given to the participating laboratories without disclosing its chemical nature. 4. The most important enzyme (CYP3A4) and metabolic route (10,11-epoxidation) were predicted by all the systems studied. 5. Minor enzymes and routes were predicted to a different extent by various systems. 6. Prediction of a clearance class, i.e. slow clearance, was correctly predicted by microsomes, slices, hepatocytes and recombinant enzymes (CYP3A4). 7. The 10,11-epoxidation of CBZ by the recombinant CYP3A4 was enhanced by the addition of exogenous cytochrome-b5, leading to a considerable over-prediction. 8. Induction potency of CBZ was predicted in cultured hepatocytes in which 7- ethoxycoumarin O-deethylase was used as an index activity. 9. It seems that for a principally CYP-metabolized substance such as CBZ, all liverderived systems provide useful information for prediction of metabolic routes, rates and interactions. 相似文献
104.
105.
Mika VJ Mustonen Seppo Pyrh?nen Pirkko-Liisa Kellokumpu-Lehtinen 《World journal of clinical oncology》2014,5(3):393-405
Although more widespread screening and routine adjuvant therapy has improved the outcome for breast cancer patients in recent years, there remains considerable scope for improving the efficacy, safety and tolerability of adjuvant therapy in the early stage disease and the treatment of advanced disease. Toremifene is a selective estrogen receptor modifier (SERM) that has been widely used for decades in hormone receptor positive breast cancer both in early and late stage disease. Its efficacy has been well established in nine prospective randomized phase III trials compared to tamoxifen involving more than 5500 patients, as well as in several large uncontrolled and non-randomized studies. Although most studies show therapeutic equivalence between the two SERMs, some show an advantage for toremifene. Several meta-analyses have also confirmed that the efficacy of toremifene is at least as good as that of tamoxifen. In terms of safety and tolerability toremifene is broadly similar to tamoxifen although there is some evidence that toremifene is less likely to cause uterine neoplasms, serious vascular events and it has a more positive effect on serum lipids than does tamoxifen. Toremifene is therefore effective and safe in the treatment of breast cancer. It provides not only a useful therapeutic alternative to tamoxifen, but may bring specific benefits. 相似文献
107.
108.
109.
110.
Why patients sign out against medical advice (AMA): factors motivating patients to sign out AMA 总被引:3,自引:0,他引:3
Green P Watts D Poole S Dhopesh V 《The American journal of drug and alcohol abuse》2004,30(2):489-493
A retrospective review of the against medical advice (AMA) discharges revealed that the majority of the patients left AMA for personal reasons, i.e., sickness or death in the family; reconciliation with spouse, girl friend, or family members; financial problems; and legal issues such as a court date. Strategies to reduce AMA discharges and increase patient retention in treatment are suggested. 相似文献